Stanley Erck, Novavax CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)

mR­NA al­ter­na­tive: No­vavax fi­nal­ly scores EUA for pri­ma­ry Covid-19 vac­cine se­ries

Al­most 7 months af­ter sub­mit­ting its EUA ap­pli­ca­tion — mean­ing the FDA’s re­view took a few months short­er than a stan­dard vac­cine re­view — No­vavax on Wednes­day fi­nal­ly cap­tured an elu­sive goal, win­ning an EUA for its 2-dose pri­ma­ry se­ries of its pro­tein-based vac­cine for adults to pre­vent Covid-19.

While some have sought an al­ter­na­tive to the mR­NA-based Covid vac­cines from Pfiz­er/BioN­Tech and Mod­er­na, both of which have now gone through FDA’s full ap­proval process (EUA ≠ Ap­proval), oth­ers ques­tion the need for an op­tion like No­vavax’s that may end up be­ing less ef­fec­tive than its com­peti­tors. John­son & John­son re­cent­ly all but pulled its one-dose ver­sion from the US mar­ket af­ter safe­ty risks arose.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.